Lantheus Holdings, Inc.: directors' dealings · United States · SEC (Form 4)

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a U.S.-based radiopharmaceutical company listed on the NASDAQ under the ticker LNTH, with its headquarters in Bedford, Massachusetts, United States. For French-speaking investors, the company sits at the intersection of nuclear medicine, diagnostic imaging and targeted therapeutics. Its roots go back to 1956, when it was founded as New England Nuclear, giving Lantheus a long operating history in a highly specialized healthcare segment. Today, the company is positioned as a radiopharmaceutical-focused platform, with a strategy centered on PET diagnostics, ultrasound microbubbles and a development pipeline aimed at oncology and neurology. ([lantheus.com](https://www.lantheus.com/about/?utm_source=openai)) The commercial portfolio is anchored by products with strong clinical relevance and established market visibility. PYLARIFY, a PSMA PET imaging agent used in prostate cancer, is the flagship product and is described by the company as the market-leading PSMA PET agent in the United States. DEFINITY is an echocardiography contrast agent and remains an important mature revenue contributor. Lantheus also markets Neuraceq, an amyloid PET radiodiagnostic used in Alzheimer’s disease assessment, while continuing to advance pipeline assets such as MK-6240 and NAV-4694. In addition, the company emphasizes manufacturing, distribution and patient-access support capabilities around its products. ([lantheus.com](https://www.lantheus.com/products/?utm_source=openai)) From a competitive standpoint, Lantheus benefits from a defensible position in niche markets where regulatory execution, isotope supply chains, PET manufacturing capacity and reimbursement are critical. The company describes itself as a leading radiopharmaceutical-focused business, with a mission to help clinicians “Find, Fight and Follow” disease. Its revenue base is still primarily U.S.-centric, but the company also has offices in Canada, Germany, Sweden, Switzerland and the United Kingdom, supporting research, partnerships and selected commercial activities. ([investor.lantheus.com](https://investor.lantheus.com/?utm_source=openai)) Recent corporate developments underline the strategic pivot. In 2025 and 2026, Lantheus continued to reorient the portfolio toward PET radiodiagnostics and divested its SPECT business to SHINE Technologies, sharpening the company’s focus on higher-growth assets. Regulatory milestones have also been important: PYLARIFY TruVu received FDA approval in March 2026, the PDUFA date for LNTH-2501 was extended to June 29, 2026, and other pipeline programs have advanced through key regulatory steps. Meanwhile, the acquisitions of Life Molecular Imaging and Evergreen Theragnostics expanded the company’s diagnostic and manufacturing capabilities, reinforcing its ambition to become a fully integrated radiopharmaceutical leader. ([investor.lantheus.com](https://investor.lantheus.com/news-releases/news-release-details/lantheus-announces-closing-spect-business-sale-shine?utm_source=openai))